Additional market coverage around Q32’s alopecia results emphasized the company’s competitive framing versus JAK inhibitors and the strength of investor reaction to new efficacy signals. Reports highlighted the share-price move and how investors interpreted the latest data as supporting a potentially safer, more durable immunomodulatory option. The read-through matters for the category because alopecia areata remains a high-unmet-need immune-mediated condition, and incremental proof points can shift expectations for clinical risk-benefit profiles and treatment durability. Taken together, the latest coverage underscores how biotech valuation in dermatology immunology is increasingly tethered to trial endpoints that translate directly into durable, patient-visible outcomes.